The PREDICT Registry:
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Inclusion Criteria
- Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
- Patient must have the DCISionRT test ordered during routine patient care.
- Patient must be eligible for or have recently completed breast conserving surgery.
- Patient must be eligible to receive radiation and/or systemic treatment.
- Patient must be 30 to 85 years old.
- Patient must have tumor size of less than 6 cm.
- Patient must have been diagnosed with DCIS within 120 days of consent.
Exclusion Criteria
- Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing.
- Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget's disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast.
- Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS.
- Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer.
- Patient has a prior history of in-field radiation in the ipsilateral breast.
- Patient has had prior systemic endocrine or chemotherapy prior to testing.
- Patient is pregnant.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03448926.
Locations matching your search criteria
United States
Colorado
Aurora
District of Columbia
Washington
Georgia
Atlanta
Decatur
Johns Creek
Illinois
Chicago
Maryland
Baltimore
Massachusetts
Boston
South Weymouth
Missouri
Saint Louis
New York
New York
Ohio
Columbus
Pennsylvania
Philadelphia
Pittsburgh
Willow Grove
Texas
Houston
After a diagnosis of DCIS, the most representative tissue block (or 10 sections mounted
on charged slides cut at 3-4 microns) will be sent to PreludeDx for DCISionRT. The most
representative specimen should be selected from tissue collected via direct tumor biopsy
(either core needle or excisional biopsy) as part of routine patient care. Patients must
be enrolled in the study and the enrollment and pre-testing data forms must be completed
and submitted before the DCISionRT results are reported. Then, after review of the
DCISionRT results, the investigators complete and submit the post-testing data form. The
patient may then be followed for up to 10 years (or until death) with completion of 5-
and 10-year follow-up forms.
All study data will be stored in an encrypted, HIPAA-compliant database maintained by the
coordinating center. Each consented patient will be assigned a unique Study ID number.
Study personnel at each institution will maintain an electronic key to link the Study IDs
of its own patients to the patients' local medical record number. All personal health
information (PHI) will remain at the local institution and only de-identified data will
be uploaded to the national registry. No genetic test results that may be used to
identify the patient will be included in the database.
This study is designed to assess the magnitude of and conditions impacting physician
treatment recommendations based on the DCISionRT test results, assessing patient
preference, and within various clinicopathologic subgroups. This will also be the largest
prospective determination of IBR outcomes with DCISionRT test result correlates to date.
Part I of the PREDICT Registry recently completed enrollment of 2,500 subjects for whom
DCISionRT results had been reported using the original test protocol that classified
patients into two risk groups, Low Risk and Elevated Risk.64
Part II of the PREDICT Registry will enroll up to an additional 3,000 subjects from 15 to
30 sites within the United States with each site enrolling between 100 and 300 patients.
DCISionRT results will be reported using the updated test protocol that classifies
patients into three risk groups, Low Risk, Elevated Risk and Residual Risk. Part II study
procedures will be conducted exactly the same as Part I, except that further patient
demographics and treatment preference, treatment recommendation details, and patient
upstaging will be collected. Additional questions will be asked to determine how
physicians use the Residual Risk group classification to make treatment decisions.
De-identified imaging data may also be collected, and de-identified patient tissue
samples may be collected after 1 year.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationPreludeDX
- Primary IDExt00000206
- Secondary IDsNCI-2020-00575, 20172841
- ClinicalTrials.gov IDNCT03448926